KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $230.5 million.

  • Halozyme Therapeutics' Other Operating Expenses rose 8.66% to $73.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.1 million, marking a year-over-year increase of 9.31%. This contributed to the annual value of $230.5 million for FY2024, which is 13.40% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Other Operating Expenses of $230.5 million as of FY2024, which was down 13.40% from $266.1 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Other Operating Expenses high stood at $266.1 million for FY2023, and its period low was $43.4 million during FY2020.
  • Over the past 3 years, Halozyme Therapeutics' median Other Operating Expenses value was $230.5 million (recorded in 2024), while the average stood at $226.4 million.
  • In the last 5 years, Halozyme Therapeutics' Other Operating Expenses soared by 124.11% in 2022 and then decreased by 13.40% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Other Operating Expenses (Yearly) stood at $43.4 million in 2020, then skyrocketed by 87.73% to $81.4 million in 2021, then surged by 124.11% to $182.5 million in 2022, then spiked by 45.87% to $266.1 million in 2023, then declined by 13.40% to $230.5 million in 2024.